Outer membrane vesicle of Neisseria meningitidis serogroup B as an adjuvant to induce specific antibody response against the lipopolysaccharide of Brucella abortus S99

Annals of Microbiology

Volumn 59, Issue 1, 2009, Pages 145-149

  Salmani, Ali Sharifat ^a,b   Siadat, Seyed Davar ^a   Norouzian, Dariush ^a   Mobarakeh, Jalal Izadi ^a   Kheirandish, Maryam ^c   Zangeneh, Mehrangiz ^b   Aghasadeghi, Mohammad Reza ^a   Nejati, Mehdi ^a   Hedayati, Mohammad Hossein ^a   Moshiri, Arfa ^d   Sadat, Seyed Mehdi ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant; Brucella abortus S99; Lipopolysaccharide (LPS); Outer membrane vesicle

Indexed keywords

ANIMALIA; BRUCELLA; BRUCELLA MELITENSIS BIOVAR ABORTUS; MUS; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B;

EID: 69549090454     PISSN: 15904261     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03175612     Document Type: Article

References (28)

1. Adlimoghadam A., Hedayati M.H., Siadat S.D., Ahmadi H., Nejati M., Vandyousefi J., Norouzian D. (2008). Optimization of PCR conditions for detection of human brucellosis from human serum samples. Res. J. Microbiol., 3 (5): 352-358.
2. Bhattacharjee A.K., Van De Verg L.V., Izadjoo M.J., Yuan L., Hadfield T.L., Zollinger W.D., Hoover D.L. (2002). Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect. Immun., 70: 3324-3329.
3. Bhattacharjee A.K., Izadjoo M.J., Zollinger W.D., Nikolich M.P., Hoover D.L. (2006). Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect. Immun., 74: 5820-5825.
4. Carmichael L.E. (1990). Brucella canis. In: Nielsen K., Duncan J.R., Eds, Animal Brucellosis. CRC Press, Inc., Boca Raton, Fla., pp. 335-350.
5. Claassen I., Meylis J., Van der Ley P., Peeters C., Brons H., Robert J., Borsboom D., van der Ark A., van Straaten I., Roholl P., Kuipers B., Poolman J. (1996). Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine, 14: 1001-1008.
6. Cloeckaert A., Jacques I., De Wergifosse P., Dubray G., Limet J.N. (1992). Protection against Brucella melitensis and Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharide. Infect. Immun., 60: 312-315.
7. Cloeckaert A., Zygmunt M.S., Dubray G., Limet J.N (1993). Characterization of O-polysaccharide-specific monoclonal antibodies derived from mice infected with the rough Brucella melitensis strain B115. J. Gen. Microbiol., 139: 1551-1556.
8. Corbel M.J. (1997). Brucellosis: an overview. Emerg. Infect. Dis., 3: 313-321.
9. Elberg S.S. (1973). Immunity to brucella infection. Medicine (Baltimore), 52: 339-356.
10. Estevez F., Carr A., Soloranzo L., Valiente O., Mesa C., Barroso O., Sierra G.V., Fernandez L.E. (1999). Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine, 18: 190-197.
11. Haneberg B., Dalseg R., Oftung F., Wedege E., Hoiby EA., Haugenb IL., Holst J., Andersen S.R., Aase A., Naess L.M., Michaelsen T.E., Namork E., Haaheim L.R. (1998). Towards a nasal vaccine against meningococcal disease,and prospects for its use as a mucosal adjuvant. In: Brown F., Haaheim L.R., Eds, Developments in Biological Standardization, Vol.92, Karger, Postfach, Ch-4009 Basel, Switzerland, pp. 127-133.
12. Jacques I., Olivier-Bernardin V., Dubray G. (1991). Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine, 9:896-900.
13. Jimenez de Bagues M.P., Dudal S., Dornald J., Gross A. (2005). Cellular bioterrorism: how Brucella corrupt macrophage physiology to promote invasion and proliferation. Clin. Immunol., 114: 227-238.
14. Lapaque N., Moriyon I., Moreno E., Gorvel J.P. (2005). Brucella lipopolysaccharide acts as a virulence factor. Curr. Opin. Microbiol., 8: 60-66.
15. Oliveira S.C., Splitter G.A. (1996). Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine, 14: 959-962.
16. Oliver K.J., Reddin K.M., Bracegirdle P., Hudson M.J., Borrow R., Feavers I.M., Robinson A., Cartwright K., Gorringe A.R. (2002). Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun., 70: 3621-3626.
17. Sanchez S., Troncoso G., Criado M.T., Ferreiros C. (2002). In vitro introduction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica. Vaccine, 20: 2957-2963.
18. Sardinas G., Reddin K., Pajon R., Gorringe A. (2006). Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine, 24: 206-214.
19. Shapouri R., Mohabati Mobarez A., Ahmadi H., Tabaraie B., Hosseini Doust R., Norouzian D., Zavaran Hosseini A., Siadat S.D. (2008). Optimization of Brucella abortus fermenter culture conditions and LPS extraction method for antigen production. Res. J. Microbiol., 3 (1): 1-8.
20. Sharifat Salmani A., Siadat S.D., Ahmadi H., Nejati M., Norouzian D., Tabaraie B., Abbasi M., Karbasian M., Mohabati Mobarez A., Shapouri R. (2008). Optimization of Brucella abortus S99 lipopolysaccharide extraction by phenol and butanol methods., Res. J. Biol. Sci., 3 (6): 576-580.
21. Siadat S.D., Norouzian D. (2007). Past, present and future perspective of meningococcal vaccine. J. Infect. Develop. Count., 1 (2): 129-146.
22. Siadat S.D., Behzadiannejad Q., Tabaraie B., Ahmadi H., Norouzian D., Najar peerayeh S., Nejati M., Zangeneh M. (2007a). Evaluation of serum bactericidal activity specific for Neisseria meningitidis serogroup A and B: effect of immunization with Neisseria meningitidis serogroup A polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Res. J. Microbiol., 2 (5): 436-444.
23. Siadat S.D., Norouzian D., Tabaraie B., Ahmadi H., Behzadiyannejad Q., Najar Pirayeeh S., Nejati M., Motlagh B.A. (2007b). Comparative studies of conjugated capsular polysaccharide of Neisseria meningitidis serogroup A with outer membrane vesicle of Neisseria meningitidis serogroup B. Res. J. Microbiol., 2 (4): 337-345. (Pubitemid 46955791)
24. Spink W.W., Hall J.W.I., Finstad J., Mallet E. (1962). Immunization with viable Brucella organisms, results of a safety test in humans. Bull. W.H.O., 26: 409-419.
25. U.S. Pharmacopeia Bacterial Endotoxins Test, USP 26 NF 21 (2003). Texas A&M University Press, College Station.
26. Van de verg L.L., Hartman A.B., Bhattacharjee A.K., Tall B.D., Yuan L., Sasala K., Hadfield T.L., Zollinger W.D., Hoover D.L., Warren R.L. (1996). Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and Guinea pig intranasal immunization models. Infect. Immun., 64: 5263-5268.
27. Winter A.J., Rowe G.E., Duncan J.R., Eis M.J., Widom J., Ganem B., Morein B. (1988). Effectiveness of natural and synthetic complexes of porin and O-polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun., 56: 2808-2817.
28. World Health Organization (1997). Fact sheet N 173, July 1997. World Health Organization, Geneva, Switzerland.